Cargando…

Significance of PIVKA-II levels for predicting microvascular invasion and tumor cell proliferation in Chinese patients with hepatitis B virus-associated hepatocellular carcinoma

The present study aimed to determine the levels of prothrombin induced by vitamin K absence-II (PIVKA-II) according to the Barcelona Clinic Liver Cancer (BCLC) staging system, to develop an appropriate strategy for managing hepatocellular carcinoma (HCC), particularly early HCC, and to investigate t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Xiao-Lu, Zhu, Jing, Wu, Jiong, Tian, Lu, Gao, Yao-Yi, Zhang, Chun-Yan, Zhou, Yan, Dai, Qian, Wang, Bei-Li, Pan, Bai-Shen, Zhou, Jian, Fan, Jia, Yang, Xin-Rong, Guo, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2018
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5950517/ https://www.ncbi.nlm.nih.gov/pubmed/29805574 http://dx.doi.org/10.3892/ol.2018.8375

Ejemplares similares

Changes and Clinical Significance of PIVKA-II in Hepatitis E Patients
por: Chen, Youran, et al.
Publicado: (2022)

Impact of PIVKA-II in diagnosis of hepatocellular carcinoma
por: Zakhary, Nadia I., et al.
Publicado: (2013)

Value of AFP and PIVKA-II in diagnosis of HBV-related hepatocellular carcinoma and prediction of vascular invasion and tumor differentiation
por: Si, Yuan-Quan, et al.
Publicado: (2020)

The Diagnostic Value of Serum PIVKA-II Alone or in Combination with AFP in Chinese Hepatocellular Carcinoma Patients
por: Xu, Fei, et al.
Publicado: (2021)

Performance of Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) for Hepatocellular Carcinoma Screening in Chinese Population
por: Yu, Rentao, et al.
Publicado: (2015)

Efficacy of PIVKA-II in prediction and early detection of hepatocellular carcinoma: a nested case-control study in Chinese patients
por: Yu, Rentao, et al.
Publicado: (2016)

Clinical evaluation of Elecsys PIVKA-II for patients with advanced hepatocellular carcinoma
por: Kaneko, Shun, et al.
Publicado: (2022)

Clinical Significance of AFP and PIVKA-II Responses for Monitoring Treatment Outcomes and Predicting Prognosis in Patients with Hepatocellular Carcinoma
por: Park, Hana, et al.
Publicado: (2013)

Corrigendum: Efficacy of PIVKA-II in prediction and early detection of hepatocellular carcinoma: a nested case-control study in Chinese patients
por: Yu, Rentao, et al.
Publicado: (2016)

Validation of combined AFP, AFP-L3, and PIVKA II for diagnosis and monitoring of hepatocellular carcinoma in Chinese patients
por: Ren, Tianying, et al.
Publicado: (2023)

Diagnostic and Prognostic Nomograms for Hepatocellular Carcinoma Based on PIVKA-II and Serum Biomarkers
por: An, Shu, et al.
Publicado: (2023)

Usefulness of PIVKA-II for monitoring after liver transplantation in patients with hepatocellular carcinoma
por: Villalba-López, Francisco, et al.
Publicado: (2023)

The diagnostic value of PIVKA‐II, AFP, AFP‐L3, CEA, and their combinations in primary and metastatic hepatocellular carcinoma
por: Qi, Famei, et al.
Publicado: (2019)

Effectiveness of PIVKA-II in the detection of hepatocellular carcinoma based on real-world clinical data
por: Yu, Rentao, et al.
Publicado: (2017)

Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma
por: Park, Sang Joon, et al.
Publicado: (2017)

PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma
por: Feng, Honglei, et al.
Publicado: (2021)

The value of PIVKA-Ⅱ versus AFP for the diagnosis and detection of postoperative changes in hepatocellular carcinoma
por: Lee, Qiuyan, et al.
Publicado: (2021)

Performance evaluation of the Elecsys PIVKA‐II and Elecsys AFP assays for hepatocellular carcinoma diagnosis
por: Chan, Henry L Y, et al.
Publicado: (2022)

Clinical value of serum AFP and PIVKA‐II for diagnosis, treatment and prognosis of hepatocellular carcinoma
por: Tian, Shan, et al.
Publicado: (2022)

Better performance of PIVKA-II for detecting hepatocellular carcinoma in patients with chronic liver disease with normal total bilirubin
por: Qian, Xiang-Jun, et al.
Publicado: (2023)

The Influence of Alcoholic Liver Disease on Serum PIVKA-II Levels in Patients without Hepatocellular Carcinoma
por: Kang, Keunhee, et al.
Publicado: (2015)

Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region
por: Kim, Do Young, et al.
Publicado: (2023)

The diagnostic performance of AFP and PIVKA-II models for non-B non-C hepatocellular carcinoma
por: Tran, Vinh Thanh, et al.
Publicado: (2023)

The Comparison of Surgical Margins and Type of Hepatic Resection for Hepatocellular Carcinoma With Microvascular Invasion
por: Liu, Jianwei, et al.
Publicado: (2023)

Diagnostic Performance of AFP, AFP-L3, or PIVKA-II for Hepatitis C Virus-Associated Hepatocellular Carcinoma: A Multicenter Analysis
por: Liu, Siyu, et al.
Publicado: (2022)

Utility of PIVKA-II and AFP in Differentiating Hepatocellular Carcinoma from Non-Malignant High-Risk Patients
por: Hadi, Hana, et al.
Publicado: (2022)

PIVKA-II or AFP has better diagnostic properties for hepatocellular carcinoma diagnosis in high-risk patients
por: Suttichaimongkol, Tanita, et al.
Publicado: (2023)

Identification of the Best Cut-Off Value of PIVKA-II for the Surveillance of Patients at Risk of Hepatocellular Carcinoma Development
por: Caviglia, Gian Paolo, et al.
Publicado: (2023)

Prognostic significance of microvascular invasion in tumor stage for hepatocellular carcinoma
por: Park, Yong Keun, et al.
Publicado: (2017)

PIVKA-II level is correlated to development of portal vein tumor thrombus in patients with HBV-related hepatocellular carcinoma
por: Li, Tao, et al.
Publicado: (2019)

The clinical application of PIVKA‐II in hepatocellular carcinoma and chronic liver diseases: A multi‐center study in China
por: Ji, Jun, et al.
Publicado: (2021)

PIVKA-II as a surrogate marker for prognosis in patients with localized hepatocellular carcinoma receiving stereotactic body radiotherapy
por: Cho, Ick Joon, et al.
Publicado: (2022)

Effect of PIVKA‐II and AFP secretion status on early recurrence of hepatocellular carcinoma after open and laparoscopic surgery
por: Cai, Yunshi, et al.
Publicado: (2023)

Primary colon cancer with a high serum PIVKA-II level
por: Kato, Kazuya, et al.
Publicado: (2014)

PIVKA-II: A biomarker for diagnosing and monitoring patients with pancreatic adenocarcinoma
por: Tartaglione, Sara, et al.
Publicado: (2021)

Unclassified hepatocellular adenoma with histological brown pigment deposition and serum PIVKA-II level elevation: a case report
por: Hoshino, Kouki, et al.
Publicado: (2020)

The potential of PIVKA-II as a treatment response biomarker in hepatocellular carcinoma: a prospective United Kingdom cohort study
por: Sagar, Vandana M., et al.
Publicado: (2021)

Investigating a Prognostic Factor for Canine Hepatocellular Carcinoma: Analysis of Different Histological Grading Systems and the Role of PIVKA-II
por: Maniscalco, Lorella, et al.
Publicado: (2022)

Identification of serologic biomarkers for predicting microvascular invasion in hepatocellular carcinoma
por: Yu, Yuan-Quan, et al.
Publicado: (2016)

Radiomics for the detection of microvascular invasion in hepatocellular carcinoma
por: Lv, Kun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hctel00gt1c92s6t8r9b1msmnp